Oral anticancer drug Nexavar granted KFDA approval

Bayer Korea announced on June 28 that the Korea Food and Drug Administration (KFDA) has approved the local marketing of Nexavar (sorafenib) tablets for the first-line treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer.

Nexavar is co-developed by Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. and has been shown to double progression free survival in patients ...